celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxorubicin-hidroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - daganatellenes szerek - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
cortef 10 mg tabletta
pfizer kft. - hidrokortizon -
imuran 25 mg filmtabletta
aspen pharma trading ltd (ie) - azatioprin -
imuran 50 mg filmtabletta
aspen pharma trading ltd (ie) - azatioprin -
medrol 16 mg tabletta
pfizer kft. - metilprednizolon -
medrol 4 mg tabletta
pfizer kft. - metilprednizolon -
medrol 32 mg tabletta
pfizer kft. - metilprednizolon -
medrol 100 mg tabletta
pfizer kft. - metilprednizolon -
solu-medrol 40 mg por és oldószer oldatos injekcióhoz
pfizer kft. - metilprednizolon -
solu-medrol 125 mg por és oldószer oldatos injekcióhoz
pfizer kft. - metilprednizolon -